{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-023447","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2025-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.385751+00:00","generated_at":"2026-05-24T21:23:34.510549+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Quoin reports FY2024 net loss $9.0M; cash $14.1M; positive QRX003 whole-body data in Netherton","bullets":["Cash of $14.1M at Dec 31, 2024 expected to fund operations into Q2 2026.","Net loss FY2024 $9.0M vs $8.7M; Q4 loss $2.3M vs $2.0M year ago.","First pediatric patient on whole-body QRX003 showed skin healing in 2 weeks, discontinued all prior meds, zero sleep disturbances.","FDA cleared whole-body QRX003 study; to be led by Dr. Amy Paller at Northwestern University.","Filed patent applications for topical rapamycin formulations targeting rare dermatological diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-023447","json":"https://secwatch.observer/filing/0001104659-25-023447.json","markdown":"https://secwatch.observer/filing/0001104659-25-023447.md","text":"https://secwatch.observer/filing/0001104659-25-023447.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465925023447/0001104659-25-023447-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465925023447/tm259112d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T21:23:34.510549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}